NO963728L - Fibroplastvekstfaktor-10 - Google Patents

Fibroplastvekstfaktor-10

Info

Publication number
NO963728L
NO963728L NO963728A NO963728A NO963728L NO 963728 L NO963728 L NO 963728L NO 963728 A NO963728 A NO 963728A NO 963728 A NO963728 A NO 963728A NO 963728 L NO963728 L NO 963728L
Authority
NO
Norway
Prior art keywords
disclosed
polypeptides
fgf
polypeptide
methods
Prior art date
Application number
NO963728A
Other languages
English (en)
Other versions
NO963728D0 (no
Inventor
Jing-Shan Hu
Jeannine D Gocayne
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NO963728D0 publication Critical patent/NO963728D0/no
Publication of NO963728L publication Critical patent/NO963728L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Humane FGF-10-polypeptider og DNA (RNA) som koder for slike FGF-10-polypeptider er beskrevet. Det er også tilveiebragt en fremgangsmåte for å fremstille et slikt polypeptid ved rekom- binante teknikker. Det er også angitt metoder for å anvende slikt polypeptid for å stimulere revaskularisering, for å behandle sår og hindre neuronal skade. Antagonister mot slike polypeptider og deres anvendelse som et terapeutika for å forhindre unormal celleproliferasjon, hypervaskulære sykdommer og epitel-linsecelleproliferasjon er også omtalt. Diagnostiske metoder for å detektere mutasjoner i FGF-10-kodesekvensen og forandringer i konsentrasjonen av FGF-10-protein i en prøve utledet fra en vert er også angitt.
NO963728A 1994-03-08 1996-09-06 Fibroplastvekstfaktor-10 NO963728L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/207,412 US5817485A (en) 1994-03-08 1994-03-08 Nucleic acids and cells for recombinant production of fibroblast growth factor-10
PCT/US1995/002950 WO1995024414A1 (en) 1994-03-08 1995-03-08 Fibroblast growth factor-10

Publications (2)

Publication Number Publication Date
NO963728D0 NO963728D0 (no) 1996-09-06
NO963728L true NO963728L (no) 1996-11-07

Family

ID=22770445

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963728A NO963728L (no) 1994-03-08 1996-09-06 Fibroplastvekstfaktor-10

Country Status (21)

Country Link
US (2) US5817485A (no)
EP (2) EP0750628B1 (no)
JP (2) JPH09510103A (no)
CN (1) CN1150804A (no)
AT (1) ATE251637T1 (no)
AU (1) AU1986195A (no)
CA (1) CA2183961A1 (no)
CZ (1) CZ260696A3 (no)
DE (1) DE69531892T2 (no)
DK (1) DK0750628T3 (no)
ES (1) ES2208676T3 (no)
FI (1) FI963475A (no)
HU (1) HUT77578A (no)
IL (1) IL112878A0 (no)
MX (1) MX9603897A (no)
NO (1) NO963728L (no)
PL (1) PL316202A1 (no)
PT (1) PT750628E (no)
SK (1) SK112996A3 (no)
WO (1) WO1995024414A1 (no)
ZA (1) ZA951886B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
WO1995024473A1 (en) 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
EP0832216A4 (en) * 1995-06-05 1999-06-16 Human Genome Sciences Inc FIBROBLAST GROWTH FACTOR 15
US6020189A (en) * 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
JPH10279501A (ja) * 1997-02-10 1998-10-20 Rohto Pharmaceut Co Ltd 育毛剤
US6335317B1 (en) * 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
KR101187871B1 (ko) 2009-09-23 2012-10-05 (주)케어젠 Ｆｇｆ１０－유래 펩타이드 및 그의 용도
WO2012071516A2 (en) * 2010-11-23 2012-05-31 Kci Licensing, Inc. Devices and methods for the diagnosis and treatment of wounds using biomarkers
CN103169658A (zh) * 2012-10-26 2013-06-26 温州医学院 成纤维细胞生长因子-10脂质体制备及在毛发再生中的应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells

Also Published As

Publication number Publication date
ZA951886B (en) 1996-09-09
CN1150804A (zh) 1997-05-28
HU9602434D0 (en) 1996-11-28
PT750628E (pt) 2004-03-31
JP2002335982A (ja) 2002-11-26
PL316202A1 (en) 1996-12-23
EP0750628B1 (en) 2003-10-08
IL112878A0 (en) 1995-06-29
MX9603897A (es) 1997-07-31
JPH09510103A (ja) 1997-10-14
AU1986195A (en) 1995-09-25
CZ260696A3 (en) 1997-05-14
EP0750628A4 (en) 1997-06-11
NO963728D0 (no) 1996-09-06
CA2183961A1 (en) 1995-09-14
EP0750628A1 (en) 1997-01-02
FI963475A (fi) 1996-11-05
DK0750628T3 (da) 2004-02-02
ES2208676T3 (es) 2004-06-16
FI963475A0 (fi) 1996-09-05
SK112996A3 (en) 1997-01-08
HUT77578A (hu) 1998-06-29
EP1380594A1 (en) 2004-01-14
US5817485A (en) 1998-10-06
WO1995024414A1 (en) 1995-09-14
DE69531892T2 (de) 2004-07-22
DE69531892D1 (de) 2003-11-13
US20020034787A1 (en) 2002-03-21
ATE251637T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
NO963728L (no) Fibroplastvekstfaktor-10
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69636752D1 (de) Menschlicher wachstumsfaktor 2, spezifisch für vaskuläre endothelzellen
DE69530944D1 (de) Keratinozyten-wachstumsfaktor 2
DE68923107T2 (de) DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI.
FI863626A (fi) Dna-sekvenser, rekombinant-dna -molekyler och foerfaranden foer framstaellning av polypeptider som liknar humant lipokortin.
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
MX9708493A (es) Factor 15 de crecimiento de fibroblastos.
MX9706854A (es) Factor 14 de crecimiento de fibroblastos.
MX9709217A (es) Factor de crecimiento 13 de fibroblastos.
MX9707897A (es) Factor-11 del crecimiento de fibroblastos.
MX9706204A (es) Factor 2 de crecimiento de queratinocitos.